TrialWiener klinische Wochenschrift2021

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.

Peter G Kremsner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.